Drugs / EngerixTM-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00880477 | Jan 2001 → Nov 2002 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01777295 Comparator | Feb 2013 → May 2016 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EngerixTM-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01777295 ↗ |
| Modality | Vaccine | “The vaccine was administered according to a 2-dose schedule” NCT00880477 ↗ |
| Route | Intramuscular | “Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.” NCT01777295 ↗ |